National Meeting Highlights from the American Pain Society

Please Log In or Register to continue.

Release Date: June 15, 2011
Expiration Date: June 15, 2012

Expected time to complete this activity as designed: 60 minutes

Program Overview

This educational initiative provides video highlights from annual pain and addiction medicine congresses. Sessions will include interesting and sometimes controversial thought leader discussions of the clinical implications on the latest development and research topics in pain management.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in pain management.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify and evaluate therapeutic implications of new conference data from the American Pain Society 2011 related to pain management.

General Information

This activity is eligible for credit through June 15, 2012. After this date, the activity will expire and no further credit will be awarded. There are no fees for participating in or receiving credit for this online educational activity.

Follow these steps to earn CME/CE credit:
1. Read the target audience, learning objectives, and author disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content.
3. Complete the educational content online as designed or printed out.
4. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score of 70% on the test and complete the Activity Evaluation to provide feedback for future programming.

Certificates may be printed immediately after successfully completing the online self-assessment post-activity and evaluation.

Faculty Biographies

Jeffrey A. Gudin, MD Moderator
Pain Management Center
Englewood Hospital and Medical Center
Englewood, New Jersey

Dr. Jeffrey A. Gudin received his medical degree from Albany Medical College in Albany, New York. Following a transitional internship in surgery, medicine, and anesthesiology at St. Barnabas Medical Center in Livingston, New Jersey, he completed a residency in anesthesiology at Yale University School of Medicine. He continued his training with an extended postdoctoral fellowship in pain medicine at the Yale Center for Pain Management, where he was actively involved in research and teaching. He is currently co-director of the Pain Management Center at Englewood Hospital and Medical Center in New Jersey, an affiliate of the Mount Sinai School of Medicine. Dr. Gudin is board certified in pain medicine and anesthesiology, and is board eligible in addiction medicine.

An active speaker in the field of pain management, Dr. Gudin has been interviewed on various television news channels, including CBS, and other national news networks. Dr. Gudin has also been quoted in The New York Times and various regional newspapers in New Jersey and Connecticut. His clinical and research focus includes pain management, regional anesthesia, and preemptive analgesia, as well as increasing clinician awareness of pain assessment and management.

Paul Arnstein, RN, PhD, FAAN
Clinical Nurse Specialist for Pain Relief
Massachusetts General Hospital 
Boston, Massachusetts

Dr. Paul Arnstein earned a doctorate in nursing from Boston College in Chestnut Hill, Massachusetts and completed research training fellowships from the National Institutes of Health. For over 30 years, he has helped thousands of patients in pain. His work with patients, professionals, and policymakers is driven by a desire to ensure that no patient lives or dies with needless pain due to unrealistic fears and mistaken beliefs about pain and its treatment. His research has been referenced in the popular media and supports the value of nurse-led interventions that help chronic pain patients think, feel, and do better.

Dr. Arnstein was a founder and first president of the New Hampshire Cancer Pain Initiative and has served as president of the New England Pain Association and the American Society for Pain Management Nursing (ASPMN). He presided over ASPMN at a time when pain management nursing emerged as a specialty within nursing. Dr. Arnstein helped develop the core curricula, exam, and certification preparation materials that have benefited over 1,000 nurses and the patients they serve. As a liaison to the Joint Commission, and an advisor to legislators through the Pain Care Forum, Dr. Arnstein has expanded nursing’s influence in promoting access to pain relievers and ensuring their safe use. 

Dr. Arnstein has participated in the development and dissemination of several position papers to help reduce pain in vulnerable populations. He is a strong spokesperson for nursing’s contributions for interdisciplinary programs and clinical guidelines developed by the American Pain Society, American Pain Foundation, and the Agency for Healthcare Research and Quality. Dr. Arnstein is widely published and frequently speaks at local, regional, and national levels addressing topics that help improve the way pain is managed.

Declan T. Barry, PhD
Assistant Professor of Psychiatry
Yale University School of Medicine
Director, APT Pain Treatment Services
New Haven, Connecticut

Dr. Declan Barry is a licensed clinical psychologist, an assistant professor in the Department of Psychiatry at Yale University School of Medicine, and director of the APT Foundation Pain Treatment Services in New Haven, Connecticut. Dr. Barry’s research is aimed at developing and evaluating treatments for patients with co-occurring opioid addiction (eg, prescription opiates, heroin) and chronic pain; and  examining the role of sociocultural factors in the occurrence and treatment of addictions (eg, eating disorders, gambling, substance-related disorders).

Jennifer Bolen, JD
Founder, The Legal Side of Pain and The Pain Lawyer™
A Division of the J. Bolen Group, LLC
Knoxville, Tennessee

Ms. Jennifer Bolen owns and operates The Legal Side of Pain®, a medico-legal consulting firm that specializing in the development and implementation of regulatory compliance programs and patient risk management protocols for the use of controlled substances to treat pain and the office-based treatment of opioid addiction. She conducts compliance audits, chart reviews, practice evaluations, and designs compliance materials for her clients nationwide. Ms. Bolen also serves as an expert legal consultant to defense counsel involved in administrative, civil, and criminal litigation. She reviews medical charts, helps legal counsel select medical experts, and assembles a litigation strategy to challenge opposing experts. She testifies on behalf of physicians concerning pain policy and regulations, and is qualified in court as a nationally recognized expert in this area. Ms. Bolen is responsible for the development of the Prescriber’s PROOF™ System, which is a documentation toolkit designed to help clinicians meet federal and state regulatory requirements for controlled substance prescribing.

In January 2006, the American Academy of Pain Medicine appointed Ms. Bolen to serve as Special Counsel to Academy Members. She is serving her third term in this position. She is the legal editor for Pain Medicine News, she serves on the editorial board for and publishes in Pain Medicine, and she also publishes in The Journal of Opioid Management and Practical Pain Management. Ms. Bolen serves as guest faculty with the University of Florida’s College of Pharmacy, and co-teaches a course on Federal Regulation of Controlled Substances.

Perry G. Fine, MD
Professor of Anesthesiology
Pain Research Center, School of Medicine
University of Utah
Salt Lake City, Utah

Dr. Perry Fine received his medical degree from the Medical College of Virginia in Richmond. He served an internship at the Community Hospital of Sonoma County in Santa Rosa, California, and completed his residency at the University of Utah Health Sciences Center in Salt Lake City. In addition, Dr. Fine completed a fellowship at the Smythe Pain Clinic of the University of Toronto in Ontario, Canada. He is a professor in the Department of Anesthesiology of the School of Medicine at the University of Utah, where he is on the faculty in the Pain Research Center, and is an attending physician in the Pain Management Center.

Currently, Dr. Fine serves on the board of directors and is president elect of the American Academy of Pain Medicine, serves on the board of directors of the American Pain Foundation, and is on the steering committee of the Pain Care Coalition, Washington, DC. He also serves as the external strategic advisor for Capital Hospice, Washington, DC developing sustainable models of advanced illness coordinated care in community settings as an integrative component of comprehensive chronic care. He is very pleased to have been selected to serve as the chair of the National Initiative on Pain Control, a broad-reaching pain improvement project of the American Pain Foundation.

Dr. Fine is widely published in the fields of pain management and end-of-life care. He serves on several scientific advisory boards and the editorial boards of several peer-reviewed medical journals. As a medical avocation, he has worked as a team physician for the University of Utah football team for the last 18 years and was a medical officer for the 2002 Winter Olympics in Salt Lake City. He is the recipient of the 2007 American Academy of Hospice and Palliative Medicine Distinguished Hospice Physician Award, and the 2008 American Pain Society John and Emma Bonica Public Service Award. In addition, in 2008, an endowed lectureship has been created in his name at West Virginia University School of Medicine (Perry G. Fine, MD Annual Lectureship in Pain and Palliative Medicine). Dr. Fine is the recipient of the American Academy of Pain Management’s 2010 “Head and Heart” award.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-11-288-H01-P. Knowledge-based CPE activity.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 11-288-271

For information on applicability and acceptance of continuing nursing education credit for this activity, please consult your professional licensing board.


In accordance with the Accreditation Council for Continuing Medical Education (ACCME), ACPE and California Board of Nursing, MediCom Worldwide, Inc. requires that all program planners, faculty, and providers who are in a position to control the content of a CE activity are required to disclose any relevant financial relationships they may have or have had within the last 12 months with the commercial supporter or the manufacturer(s) of any commercial device(s) discussed in this educational activity. Accordingly the following disclosures were made.

Faculty Disclosures

Dr. Jeffrey Gudin has received honoraria related to speakers’ bureau activities from Cephalon, Inc., King Pharmaceuticals, Inc., Pfizer Inc., and Purdue Pharma L.P.

Dr. Paul Arnstein has received consultant fees related to formal advisory activities from Cephalon, Inc.

Dr. Declan Barry has disclosed no relevant financial relationships with the grantor or any other commercial company whose products and services may be related to his presentation

Jennifer Bolen has received consultant fees from Abbott Laboratories, Avee Laboratories, Inc., Capital Tox, Cephalon, Inc., King Pharmaceuticals, Inc., Meda Pharmaceuticals Inc., and Millennium Pharmaceuticals, Inc. as well as honoraria related speakers’ bureau activities from Calloway Labs, Capital Tox, Cephalon, and PriCara®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. She owns significant holdings in Abbott and King.

Dr. Perry Fine has received honoraria related to formal advisory activities from Ameritox, Ltd., Cephalon, Inc., Covidien, King Pharmaceuticals, Inc., Meda Pharmaceuticals Inc., and Purdue Pharma L.P., as well as honoraria related to speakers’ bureau activities from Johnson & Johnson Services, Inc. He has received consultant fees from Cephalon and Johnson & Johnson.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, Bronwyn Boyes, PharmD, director, and Alan Vogenberg, RPh, FASCP, clinical advisor, have no relevant financial relationships.

Adam J. Carinci, MD, was the clinical reviewer for this activity and has no relevant financial relationships.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Drs. Gudin, Arnstein, Barry, Brown and Ms. Bolen have indicated that their presentations would not include the discussion of unlabeled uses of commercial products or investigational/unapproved products not yet approved by the FDA for any use in the United States.

Dr. Fine indicated that his presentation would include the discussion of unlabeled uses of commercial products or investigational/unapproved products not yet approved by the FDA for certain uses in the United States.

Hardware/Software Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 7.0 or higher, or Firefox 3.0 or higher, a computer running Windows® XP, Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may be Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.

This activity is supported by independent educational grants from Endo Pharmaceuticals and Cephalon, Inc.

©2011 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.